文献速递外周动脉疾病

355 nm激光治疗膝下动脉的前瞻性多中心单臂研究12个月最终结果

Twelve-Month Outcomes of the Prospective, Multicenter, Single-Arm Study of the 355-nm Laser for Treatment of Below-the-Knee Arteries: Final Results of the Auryon BTK.
PubMed 文献 · J Endovasc Ther · 2025-07-16

Auryon BTK研究前瞻性纳入4个美国中心的60例慢性肢体威胁性缺血(CLTI)患者(61处病变),评估355 nm激光斑块旋切术的12个月结局。结果显示免于靶病变血运重建(TLR)比例为94.2%,Rutherford-Becker分级、步行障碍问卷和生活质量(EQ-5D)均有改善。

要点

  • 12个月免于TLR比例为94.2%,免于TVR为89.4%。
  • 67.6%患者Rutherford-Becker分级改善≥1级。
  • 严重钙化(59%)和慢性完全闭塞(31.1%)病变中仍获良好结局。

核心结论

  • 355 nm激光治疗膝下动脉病变12个月免于TLR率高,Rutherford-Becker分级、WIQ和生活质量(EQ-5D)显著改善。

研究设计与样本

  • 前瞻性、多中心、单臂研究,4个美国中心纳入60例CLTI患者共61处病变。
  • 12个月时42例仍在研究中(7例失访、5例退出、7例死亡)。

主要发现

  • 12个月比例分析免于TLR为94.2%,免于TVR为89.4%;Kaplan-Meier分析免于TLR为94.0%。
  • WIQ中位评分基线至3个月(p=0.0020)和基线至6个月(p=0.0290)有显著差异,基线至12个月无显著差异(Δ-0.073,p=0.678)。
  • 12个月时33.3%(4/12)患者伤口愈合。
  • EQ-5D总分中位数基线至30天(p=0.0030)、3个月(p=0.0060)、6个月(p=0.0500)和12个月(p=0.00005)均有显著差异。
  • 30天ABI与基线ABI中位数差异显著(p<0.0005),12个月ABI与基线ABI差异p=0.2100;67.6%(23/34)患者Rutherford-Becker分级改善≥1级。

关键数值与推荐

  • 临床通畅定义为收缩期峰值流速比≤2.4且无TLR。
  • 主要不良肢体事件包括截肢、靶血管血运重建和/或全因死亡。
  • 救性支架置入率为1.6%(1/61处病变)。

临床怎么用

  • Auryon 355 nm激光可用于膝下各形态病变(包括严重钙化)的血管准备,再辅以球囊扩张。
  • 激光治疗后12个月TLR率低且生活质量改善,可考虑用于CLTI膝下动脉病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Auryon laser atherectomy system has been shown to have high procedural success in the prospective, multicenter Auryon BTK study. We present the 12-month outcomes of the Auryon BTK in treating infrapopliteal arterial disease in patients with chronic limb-threatening ischemia (CLTI). METHODS: Patients at 4 US centers with CLTI were prospectively enrolled in the Auryon BTK study after obtaining informed consent. The study was approved by a central ethics committee. The 30-day primary safety and procedural success were recently published. Secondary endpoints included target lesion revascularization (TLR), clinical patency (defined as peak systolic velocity ratio ≤2.4 and no TLR), major adverse limb events (amputation, target vessel revascularization, and/or all-cause mortality), Walking Impairment Questionnaire (WIQ), Rutherford Becker (RB) category, and EQ-5D quality of life questionnaire. Proportional and Kaplan-Meier (K-M) survival analysis were performed. RESULTS: A total of 60 patients (61 lesions) were enrolled. At 12-month, 42 patients were still in the study (7 lost-to-follow-up, 5 withdrawals, 7 deceased). The mean age was 74.6 ± 10.3 years with 58.3% diabetics, 43.3% RB IV, and 56.7% RB V. Of the 61 lesions, 59% had severe calcification, 31.1% were chronic total occlusions, and 90.2% were de novo disease. Bailout stenting occurred in 1/61 lesions (1.6%). Proportional analysis for freedom from TLR at 1-year was 94.2%, and TVR was 89.4%. K-M analysis for freedom from TLR was 94.0% at 12-month. There was a significant difference in median WIQ score from to baseline to 3-month (p = 0.0020) and baseline to 6-month (p = 0.0290) but not from baseline to 12-month (Δ-0.073, p = 0.678). Wounds healed in 33.3% (n = 4/12) of patients at 12-month. There was also a significant difference in median EQ-5D total score from baseline to 30-day (p = 0.0030), 3-month (p = 0.0060), 6-month (p = 0.0500), and 12-month (p = 0.00005). In addition, there was a significant median difference between 30-day ankle-brachial index (ABI) and baseline ABI (p < 0.0005) and the 12-month ABI and baseline ABI (p = 0.2100). Rutherford-Becker category improved by ≥1 category among 67.6% (n = 23/34) patients, stayed the same in 29.4% (n = 10/34) patients and worsened in 2.9% (n = 1/34) patients at 1-year. CONCLUSION: The 355-mm laser has a high rate of freedom from TLR at 12-month with a significant improvement in RB categories, WIQ and quality of life (EQ-5D).Clinical ImpactThe Auryon BTK demonstrates the safety and effectiveness of the 355-nm Auryon laser system in treating infrapopliteal arterial disease in patients with critical limb ischemia yielding high freedom from TLR and improvement in quality of life despite complex disease. The Auryon laser can treat all lesion morphologies below the knee including severe calcium and needs to be considered by operators for vessel prepping prior to adjunctive balloon angioplasty.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Shammas NW, Yates T, Sastry A, et al. Twelve-Month Outcomes of the Prospective, Multicenter, Single-Arm Study of the 355-nm Laser for Treatment of Below-the-Knee Arteries: Final Results of the Auryon BTK. J Endovasc Ther. 2025. PMID: 40667814. doi:10.1177/15266028251352772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。